Are circulating endotrophin levels associated with future poor outcomes in patients with heart failure?
Circulating endotrophin is a prognostic biomarker associated with poor future outcomes in patients with heart failure, especially those with HFpEF.
Circulating endotrophin levels are independently associated with future poor outcomes in patients with HF, particularly in HFpEF. (Funded by Bristol Myers Squibb; Instituto de Salud Carlos III Spain and European Regional Development Fund; European Commission CRUCIAL project; and the U.S. National Institutes of Health National Heart, Lung, and Blood Institute.).
Chirinos et al. (Tue,) studied this question.